Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors

Authors

  • Line V. Hjelle Department of Clinical Medicine, Arctic University of Tromsø, Norway; ;Department of Oncology, University Hospital of North Norway, Tromsø, Norway
  • Per O. M. Gundersen Department of Clinical Pharmacology, St. Olav’s University Hospital, Trondheim, Norway
  • Ragnhild Hellesnes Department of Oncology, University Hospital of North Norway, Tromsø, Norway
  • Mette Sprauten Department of Oncology, Oslo University Hospital the Norwegian Radium Hospital, Oslo, Norway
  • Marianne Brydøy Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
  • Torgrim Tandstad The cancer Clinic, St. Olav’s University Hospital, Trondheim, Norway
  • Tom Wilsgaard Department of Community Medicine, Arctic University of Tromsø, Tromsø, Norway
  • Sophie D. Fosså Department of Oncology, Oslo University Hospital the Norwegian Radium Hospital, Oslo, Norway; ;Medical Faculty, University of Oslo, Norway; ;Cancer Registry of Norway, Oslo, Norway
  • Jan Oldenburg Medical Faculty, University of Oslo, Norway; ;Department of Oncology, Akershus University Hospital, Oslo, Norway
  • Roy M. Bremnes Department of Clinical Medicine, Arctic University of Tromsø, Norway; ;Department of Oncology, University Hospital of North Norway, Tromsø, Norway
  • Hege S. Haugnes Department of Clinical Medicine, Arctic University of Tromsø, Norway; ;Department of Oncology, University Hospital of North Norway, Tromsø, Norway

DOI:

https://doi.org/10.1080/0284186X.2018.1473641

Abstract

Background: The long-term toxicities after cisplatin-based chemotherapy (CBCT) reveal a remarkable inter-individual variation among testicular cancer survivors (TCSs). Therefore, we assessed long-term platinum (Pt) changes and their associations with CBCT-related late effects in TCSs.

Material and methods: In 77 TCSs treated with CBCT from 1984 to 1990, blood samples for analyses of Pt and a questionnaire including self-reported neuro- and ototoxicity (NTX) symptoms were collected during two follow-up surveys at median 12 (Survey I; SI) and 20 (Survey II; SII) years after treatment. Information about second cancers after SII was retrieved from the Norwegian Cancer Registry.

Results: A larger Pt decline from SI to SII was associated with a decreased risk of a second cancer diagnosis (HR 0.78, 95% CI 0.62–0.99 per 10 ng/L/year), and worsening of paresthesias in hands (OR 1.98, 95% CI 1.09–3.59 per 10 ng/L/year) and tinnitus (OR 1.51, 95% CI 1.01–2.27 per 10 ng/L/year).

Conclusion: In summary, we found a significant association between a larger Pt decline and a reduced risk of second cancers and deterioration of paresthesias in hands and tinnitus.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2018-10-03

How to Cite

Hjelle, L. V. ., Gundersen, P. O. M. ., Hellesnes, R. ., Sprauten, M. ., Brydøy, M. ., Tandstad, T. ., … Haugnes, H. S. . (2018). Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors. Acta Oncologica, 57(10), 1392–1400. https://doi.org/10.1080/0284186X.2018.1473641

Issue

Vol. 57 No. 10 (2018): Acta Oncologica

Section

Articles